|
|
Analysis of related factors of fatty liver in patients with schizophrenia |
AN Bang1 ZHAO Shanshan1 GAO Huirong1 TANG Shuyu1 JIA Yingxia1 YANG Xiaobo2 |
1.Department of Psychiatric, Xianyang Central Hospital, Shaanxi Province, Xianyang 712000, China;
2.Department of Mental and Psychological Health, the First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, Xi’an 710061, China |
|
|
Abstract Objective To explore the related factors of schizophrenic patients with fatty liver. Methods A total of 300 schizophrenic patients admitted to Xianyang Central Hospital of Shaanxi Province from January 2018 to December 2019 were selected as study subjects. According to the diagnosis results of fatty liver, they were divided into the fatty liver group and the non-fatty liver group, with 150 patients in each group. The basic data and clinical data of the two groups were compared and analyzed, and single factor analysis and multi-factor logistic regression analysis were used to explore the risk factors of fatty liver in schizophrenia. Results There were significant difference in body mass index (BMI), disease course, history of hyperlipidemia, application of antipsychotic drugs (APS) between two groups (P < 0.05). Multi-factor logistic regression analysis showed that BMI, disease course, history of hyperlipidemia, types of APS were independent risk factors of fatty liver in schizophrenics(P < 0.05). Conclusion There is a high incidence of fatty liver in schizophrenics during the treatment. The incidence of fatty liver is affected by the degree of obesity, the course of disease, the history of hyperlipidemia and the use of APS.
|
|
|
|
|
[1] 熊天秀.精神分裂症患者临床特点及中西医治疗[J].中医临床研究,2015,7(2):90-91.
[2] 董倩,董莹莹,贾敏,等.精神分裂症患者症状特征与认知功能的关系[J].西安交通大学学报:医学版,2019,40(4):604-607.
[3] 吕文标,周爱华,鲍喜燕.精神分裂症伴非酒精性脂肪肝患者血浆瘦素水平[J].中国健康心理学杂志,2014,22(6):821-824.
[4] 毛英莹,王伟梁,李辞,等.精神分裂症患者病耻感与精神残疾的关系:有调节的中介效应分析[J].中国全科医学,2020,23(20):2509-2513.
[5] 王超芬.长期服用抗精神病药物对精神分裂症患者代谢的影响[J].临床合理用药杂志,2020,13(13):48-49.
[6] 付莲花,邹凤华,余海根.首发精神分裂症患者糖脂代谢异常分析[J].中国医学创新,2019,16(32):138-142.
[7] 张惠剑.精神分裂症患者长期服用氯氮平所致药源性脂肪肝分析[J].中国药物与临床,2015,15(1):123-124.
[8] 焦玉梅,王金和,陈剑华,等.住院精神分裂症患者伴发非酒精性脂肪肝情况[J].中国心理卫生杂志,2006,(12):807-810.
[9] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-947.
[11] 郑航霄,白丽,章连生.探讨精神分裂症和非酒精性脂肪肝的相关性[J].中国病案,2011,12(12):33-35.
[12] 鲁君,王浩宇,陶浩祥.抗精神分裂症药物对非酒精性脂肪肝的影响[J].医药导报,2013,32(10):1311-1313.
[13] Hansbauer M,Wobrock T,Kunze B,et al. Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms [J]. Psychiatry Res,2018,263:22-29.
[14] 王晶.首发精神分裂症患者脂肪肝患病情况及影响因素研究[D].天津:天津医科大学,2018:23-24.
[15] 谈力欣,刘焱,张秀云,等.2型糖尿病并发非酒精性脂肪肝患者生化指标、胰岛功能和周围神经功能的临床研究[J].河北医科大学学报,2018,39(7):773-778.
[16] 陶云海,申变红,朱春燕,等.精神分裂症患者长期应用抗精神病药治疗后肝脏及血脂变化情况分析[J].中华全科医学,2016,14(4):559-560,617.
[17] 姚诚子,冯巩,宇文思,等.非酒精性脂肪性肝病发生及进展的危险因素[J].临床肝胆病杂志,2020,36(2):433-436.
[18] San Ang M,Nurjono M,Lee J. The effects of clinical illness severity and physical activity on health-related quality of life in schizophrenia [J]. Qual Life Res,2019, 28(6):1509-1520.
[19] 李静,袁捷,周雪丽,等.住院精神分裂症患者并发非酒精性脂肪肝的危险因素分析[J].肝脏,2017,22(12):1155-1157.
[20] 伊慧.精神分裂症患者肝脏彩色多普勒超声检查的临床价值分析[J].基层医学论坛,2018,22(19):2701-2702.
[21] 冯薇,朱好辉,史玉洁,等.长期服用奥氮平患者的肝脏超声特点及相关因素分析[J].国际精神病学杂志,2019, 46(3):467-469.
[22] 曹莹.2型糖尿病合并非酒精性脂肪肝的临床研究[J].糖尿病新世界,2017,20(4):33-34.
[23] Abraham VV,Filipe B,Daniel J,et al. T218. Reduced Amplitude of Fixation-Related Potentials Predicts Impaired Serial Search Performance in Schizophrenia [J]. Bio Psy,2018,83(9):213-218.
[24] 王峰,谢红涛.住院精神分裂症患者伴发非酒精性脂肪肝的相关因素分析[A].//中华医学会精神病学分会.中华医学会精神病学分会第九次全国学术会议论文集[C].中华医学会精神病学分会:中华医学会精神病学分会,2011:1.
[25] 陈宁.精神分裂症患者并发非酒精性脂肪肝的相关因素分析[J].胃肠病学和肝病学杂志,2008(11):927-929. |
|
|
|